NCT04772365: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects |
|
|
| Completed | 1 | 52 | RoW | SHR-1819, Placebo | Shanghai Hengrui Pharmaceutical Co., Ltd. | Asthma | 12/21 | 12/21 | | |
NCT05197023: A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS |
|
|
| Not yet recruiting | 1 | 20 | NA | SHR-1819 injection or placebo | Shanghai Hengrui Pharmaceutical Co., Ltd. | Moderate to Severe Atopic Dermatitis | 06/22 | 06/22 | | |
